The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Tamibarotene combined with azacitidine and venetoclax to treat AML and MDS with RARA abnormalities
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses clinical trials evaluating tamibarotene in combination with azacitidine and venetoclax for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Approximately 30% of patients with AML and MDS have abnormalities in the RARA gene, which tamibarotene targets, potentially making it effective for these patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
